Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496265 | 0.89 | F10 (0.56) | F10 | |
| SCHEMBL13780947 | 0.86 | F10 (0.61) | F10 | |
| SCHEMBL15494713 | 0.85 | F10 (0.70) | F10 | |
| Eribaxaban SCHEMBL16436969 | 0.83 | F10 (1.00) | F10 | |
| Eribaxaban SCHEMBL76436 | 0.83 | F10 (1.00) | F10 | |
| Eribaxaban SCHEMBL17294640 | 0.83 | F10 (1.00) | F10 | |
| SCHEMBL3828763 | 0.82 | F10 (0.49) | F10 | |
| SCHEMBL13674870 | 0.82 | F10 (0.62) | F10 | |
| SCHEMBL4492695 | 0.82 | F10 (0.49) | F10 | |
| SCHEMBL3828777 | 0.82 | F10 (0.48) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194643-A1 | Factor Xa Inhibitor Crystalline Forms | PFZER INC | 2008-08-14 | — | — | US | disclosed |
| EP-1891044-A1 | CRYSTALLINE FORMS OF A KNOWN PYRROLIDINE FACTOR XA INHIBITOR | Warner-Lambert Company LLC (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006100565-A1 | CRYSTALLINE FORMS OF A KNOWN PYRROLIDINE FACTOR XA INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194643-A1 | Factor Xa Inhibitor Crystalline Forms | F2, F12, F2R | F10 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.